A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• Has histologically or cytologically confirmed diagnosis of squamous or non-squamousNon-small Cell Lung Cancer (NSCLC).

• Must provide archival tumor tissue sample or newly obtained core, incisional, orexcisional biopsy of a tumor lesion not previously irradiated.

• Has a life expectancy of at least 3 months.

Exclusion Criteria:

• Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of smallcell elements.

• Has received prior systemic anticancer therapy for metastatic NSCLC.

• Has received prior systemic anticancer therapy including investigational agentswithin 4 weeks before randomization.

• Has received prior radiotherapy within 2 weeks of start of study intervention or hasradiation-related toxicity requiring corticosteroids.

• Has received radiation therapy to the lung (>30 Gray) within 6 months of start ofstudy intervention.

• Has received a live or live-attenuated vaccine within 30 days before the first doseof study intervention.

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroidtherapy.

• Has a known additional malignancy that is progressing or has required activetreatment within the past 3 years.

• Has an active autoimmune disease that has required systemic treatment in past 2years.

• Has an active infection requiring systemic therapy.

• Has a history of human immunodeficiency virus (HIV) infection.

• Has a history of Hepatitis B or C.

• Has not adequately recovered from major surgery or has ongoing surgicalcomplications.

• Has a history of allogenic tissue/solid organ transplant.